Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice
Open Access
- 2 December 2009
- journal article
- clinical trial
- Published by Elsevier BV in Annals of Oncology
- Vol. 22 (9), 2021-2030
- https://doi.org/10.1093/annonc/mdp547
Abstract
Background: The 70-gene prognosis signature has strong prognostic value in node-negative breast cancer, independent of established prognostic factors. It is unclear whether all node-negative patients should receive a signature result. We therefore evaluated its additional prognostic information to a combination of established prognostic guidelines. Methods: We evaluated 701 patients from three previously described series in whom a signature result was available. Clinical risk was on the basis of Adjuvant! Online (AO), St Gallen guidelines (St G) and Nottingham Prognostic Index (NPI). Overall survival (OS) analyses were carried out in patients treated at the Netherlands Cancer Institute (Amsterdam) who did not receive adjuvant systemic treatment (AST). Results: Only 6% (10 of 156) of estrogen receptor (ER)-negative tumours had a good prognosis signature. The signature was not useful for ER-positive tumours and concordant high AO, high St G and/or high NPI clinical risks (N = 139). The 10-year OS estimate for good signature tumours with these characteristics was 90%). Conclusion: The 70-gene prognosis signature provides additional prognostic information especially in ER-positive lymph node-negative breast cancer patients with a predominant low or discordant clinical risk on the basis of AO, St G and/or NPI.This publication has 22 references indexed in Scilit:
- Validation of 70-gene prognosis signature in node-negative breast cancerBreast Cancer Research and Treatment, 2008
- Molecular profiles of progesterone receptor loss in human breast tumorsBreast Cancer Research and Treatment, 2008
- Clinical Application of the 70-Gene Profile: The MINDACT TrialJournal of Clinical Oncology, 2008
- Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)The Lancet Oncology, 2007
- Converting a breast cancer microarray signature into a high-throughput diagnostic testBMC Genomics, 2006
- Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trialNature Clinical Practice Oncology, 2006
- Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast CancerJNCI Journal of the National Cancer Institute, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002